Beijing Jiashi Lianbo Pharmaceutical Technology

Beijing Jiashi Lianbo Pharmaceutical Technology is a Chinese biotechnology company focused on the discovery and development of innovative small molecule drugs, particularly in the fields of respiratory and metabolic diseases. The company is best known for developing Bencycloquidium Bromide (brand name Biliting), a first-in-class muscarinic receptor antagonist approved in China for the treatment of allergic rhinitis. Beijing Jiashi Lianbo operates as a research-driven entity, often collaborating with Yingu Pharmaceutical for the clinical development and commercialization of its candidates. Its pipeline includes treatments for chronic obstructive pulmonary disease (COPD) and obesity, leveraging its expertise in medicinal chemistry and pharmacology. The company has successfully transitioned from early-stage research to having a commercialized product in the Chinese market.